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doi:10.1016/j.ejvs.2011.02.025Abstract Objective: The common femoral artery (CFA) is an unusual location for endovascu-
lar repair (ER). We report the early results after ER of the CFA in a single centre.
Design: This is a cohort study.
Materials/Methods: From 2006 to 2008, ER of the CFA was proposed to 36 patients (mean age
67.9, range 51e92). CFA lesions were classified into four types: in type I, lesions were located
at the iliac external artery and were extended to the CFA; in type II, lesions were limited to the
CFA; in type III, lesions were located at the CFA and its bifurcation; type IV represents reste-
nosis bypass anastomosis. All patients were treated by stenting.
Results: Indications for ER of the CFA included 25 patients (70%) for claudication and 11
patients (30%) for critical limb ischaemia. Forty-three stents were implanted. The mean
follow-up was 22 months (range, 12e42). At 1 year, primary and secondary sustained clinical
improvements were 80% and 90%; target lesion revascularisation and target extremity revascu-
larisation free cumulative survival were 85% and 80%, respectively, and in-stent restenosis rate
was 20%. One stent fracture was noted.
Conclusions: ER of CFA and concomitant arterial lesions seems to be a safe technique with
acceptable clinical outcome at 1 year.
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ty for Vascular Surgery. PublisheOver the past years, endovascular interventions have become
an important part of treatment in patients with peripheral
arterial disease.1 Even though the indication for endovascular
therapy has been enlarged, open repair of common femoral
artery (CFA) is still considered as the treatment of choice.
Recent studies confirm its safety and its efficacy.2e4 Treat-
ment of CFA by endovascular therapy is avoided in this highly
mobile area because of the risk of stent fracture and becaused by Elsevier Ltd. All rights reserved.
788 L. Aze´ma et al.it compromises future surgical options,5,6 but is also based on
the good results of open repair.
However, the evidence to support open repair as the
standard treatment of CFA disease is not so obvious. First,
studies have reported high rates of perioperative compli-
cations following CFA endarterectomy.2,3 In 2001, Cardon
et al. reported a local morbidity rate of 21.6% after
common femoral endarterectomy with 18% of minor
complications and 3.6% of complications requiring a second
operation. More recently, Kang et al. noted 5% of major
complications requiring re-intervention and 9% of minor
complications, which were treated conservatively. All these
studies were retrospective and complications, such as
postoperative dysaesthesia, were underestimated. Second,
analysis of the anatomical behaviour of CFA during move-
ments shows that CFA is a relatively fixed artery between
the inguinal ligament above and the Sartorius muscle
below.7 Third, newer generations of nitinol stent could
expand endovascular treatment for periarticular locations
thanks to their resistance to compression and fracture in
the tortuous physical environment.5,8
Few data are available on the treatment of CFA by
emerging endovascular techniques.9,10 Herein, we report
the early outcomes of CFA primary stenting.
Materials and Methods
Experimental design/setting
From June 2006 to October 2008, endovascular therapy was
considered for CFA occlusive disease. All patients received
oral and written information about the procedure and the
lack of an existing long-term efficacy study. Inclusion
criteria included intermittent claudication or critical
ischaemia due to atherosclerotic disease (Rutherford stages
2e5), and a haemodynamically significant lesion (diameter
reduction of >70% detected by duplex scan and confirmed
by computed tomography (CT) scan or magnetic resonance
(MR) imaging). Patients with CFA thrombosis were
excluded. Patients with claudication underwent conserva-
tive therapy for 3e6 months before surgical procedure.
Each patient may have either one or both limbs treated in
the study.
The endovascular technique was proposed as a first-line
treatment in all patients. The first endovascular cases were
high-risk patients with severe co-morbidities (classified as
type 3 and 4 according to the American Society of Anes-
thesiologists score) with claudication or critical limb
ischaemia. During the last months of the series, with an
increase in expertise and confidence, the endovascular
repair was proposed for all patients as a first-line treatment.
CFA occlusive disease classification (Fig. 1)
Based on findings by Lopez et al7 and patientmedical history,
we classified CFA occlusive lesions into four groups. Type I
represents lesions that are located at the iliac external
artery and are extended to the CFA. In type II, lesions are
limited to the CFA. Type III represents lesions that are
located at the CFA and its bifurcation. Finally, type IV
represents proximal or distal stenosis bypass anastomoses.Endovascular procedures
All procedures were performed in the operating room by
vascular surgeons. Anaesthesiologists examined all patients
preoperatively. Local anaesthesia with conscious sedation
was indicated, unless general anaesthesia was needed in
patients who were restless and in pain. Access to the culprit
lesion was achieved either by way of an over-the-aortic
bifurcation approach with the use of a dedicated 6-F or 7-F-
long sheath (45 cm) (Destination, Terumo, St Quentin en
Yvelines, France) or via a brachial approach with the use of
a dedicated 6-F or 7-F-long sheath (90 cm) (Destination,
Terumo). After sheath placement, an intravenous bolus of
50 UI kg1 of heparin was given. Digital subtraction angi-
ography (DSA) was performed to assess lesions. After
successful passage of the target lesions with a hydrophilic
0.035-inch guide wire, primary stenting without lesion
predilatation was preferably performed. In type III lesions,
balloon-expandable stents were used to treat ostial
stenoses of superficial and deep femoral arteries. In type III
lesions, the superficial femoral artery (SFA) was abandoned
if it was occluded at the origin, with a stent placed from the
CFA into the profunda femoral artery. In tight stenosis that
precluded stent advancement, angioplasty with a 3-mm
balloon was done to allow stent placement. The stent
dimensions were chosen such that the nominal diameter
was equal to the reference vessel diameter and the length
exceeded the lesion length by 5e10 mm proximal and
distal. Vessel sizes were determined on the basis of
preoperative CT scan or MR imaging. The intention was to
cover the lesion with a single stent. The last generation of
self-expandable stents (Everflex, EV3, Paris; E. Luminexx
and Flexstar, Bard, Voisins le Bretonneux) was used.
Balloon-expandable stents (Amiia, Cordis, Issy Les Mouli-
neaux) were used only for type III lesions. Self-expandable
stents were routinely post-dilated. The balloon dimensions
(Optapro, Cordis, Issy Les Moulineaux) were chosen such
that the nominal diameter was inferior to the stent diam-
eter by 1 mm to reduce medial damage11 and the length did
not exceed the stent length. The technical result of the
procedure was assessed by DSA.
Groin and brachial closure was accomplished via manual
compression. In some cases, a vascular closure device
(Angioseal, St Jude Medical, Issy Les Moulineaux) was used
to seal the femoral artery puncture.
A prophylactic dose of low-molecular-weight heparin
was given during the duration of hospitalisation to prevent
venous thrombo-embolic events. Postoperatively, patients
were prescribed aspirin (75e160 mg day1) and clopidogrel
(75 mg day1) for 6 months. After 6 months, patients were
prescribed only clopidogrel (75 mg day1).12e14Follow-up
Postoperatively, patients were prospectively followed-up on
an outpatient basis. Major adverse clinical events (MACE)
were intentionally sought. Follow-up included clinical,
duplex ultrasound examinations and biplane X-ray at 1, 6 and
12 months and yearly thereafter. Patient data, imaging
parameters, intraoperative data and postoperative events
were recorded prospectively in a computerised database.
Figure 1 Common femoral artery occlusive disease classification. 1A: Type I lesion; 1B: Type II lesion; 1C: Type III lesion; 1D: Type
IV lesion.
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The main end point was primary sustained clinical improve-
ment. Secondary end points were procedural success,
secondary sustained clinical improvement, MACE, primary
patency, target lesion revascularisation (TLR), target
extremity revascularisation (TER), in-stent restenosis and
stent fracture. Detailed definitions of outcome are as follows:
Primary sustained clinical improvement was defined as
a sustained upward shift of 1 category of the Rutherford
classification without the need for repeated TLR in surviving
patients. Secondary sustained clinical improvement was
defined as a sustained upward shift of 1 category of the
Rutherford classification including the need for repeatedTLR
in surviving patients. MACE included all deaths, major
amputation, procedural-related serious adverse events and
device failure or malfunction. TLR expresses the frequency
of the need for repeated procedures (endovascular or
surgical) due to a problem arising from the lesion initially
treated (þ1 cm proximally and distally to include edge
phenomena) in surviving patients with preserved limb. TER
expresses the frequency of the need for repeatedprocedures
(endovascular or surgical) due to a problem arising remote
from the lesion initially treated in surviving patients with
preserved limb.15 Procedural success was defined by the
ability to cross the lesion with the guide wire and to inflate
the artery with a stent. Primary patency was defined as
patencywithout any percutaneous or surgical intervention in
the CFA or in the adjacent areas. Patency and in-stent
restenosis were assessed by duplex ultrasound. In-restenosis
was defined by restenosis of >50% and by a peak systolic
velocity index >2.4 at the target lesion.16 Patients were
definedas lost to follow-upwhenno further follow-up studies
were available beyond a particular completed follow-up
interval. Theoccurrenceof stent fracturewasdeterminedby
biplane radiography at 1, 6 and 12 months. Stent fractures
were classified according to the Jaff et al. classification.17
Statistical analysis
Statistical analysis results were reported prospectively on an
intent-to-treat basis and analysed. Continuous variableswere presented asmean SD, categorical variables as count
and percent. Demographic and co-morbidity data were
recorded per patient and patency data were calculated on
a per limb basis. Survival rate curves for TLR/TER were
plotted and calculated using the KaplaneMeier method. The
time occurrence of events (TER/TLR) was analysed with
a univariate Cox proportional-hazards model to assess the
specific effect of each predictor. Predictive factors included
age, sex, presence or absence of diabetes, stage of periph-
eral artery disease, types of CFA lesions, types of stents
(balloon-expendable and self-expandable stents), The Inter-
Society Consensus for Management of PAD (TASC) status and
runoff. In patients who died before the final follow-up
examination or in patients lost to follow-up, we have taken
account of the status of the last follow-up examination. In-
stent restenosis at 12 months was analysed with univariate
logistic models. A p < 0.05 was considered statistically
significant. Data were analysed using the Statistical Package
for Social Sciences (SPSS) (SPSS Inc., Chicago, IL, USA).
Results
Patients’ characteristics and demographics (Table 1)
From June 2006 to October 2008, 36 patients were treated
for CFA occlusive disease by endovascular repair in 40
limbs. The baseline characteristics of the study population
are described in Table 1. The mean age was 67.3 years.
Most of the patients were scored 3 (61%) according to the
American Society of Anesthesiologists. Indications for
intervention included 28 limbs (70%) for claudication and 12
limbs (30%) for critical limb ischaemia.
Intraoperative data (Tables 2 and 3)
Classification of the lesions is summarised in Table 2. For type
IV lesions, two proximal and three distal stenosis bypass
anastomoses were treated. Local anaesthesia was used in 33
patients (91.6%). Procedural success was 100%. No dissection
or arterial rupture was observed. No open surgery for
conversion was required. The over-the-bifurcation approach
Table 1 Baseline patient’s characteristics.
Variables
Age, yr (mean SD) 67.3  11.7
Male sex e no. (%) 30 (83%)
American Society of Anesthesiologists (ASA) score
ASA 1 0
ASA 2 11 (30.7%)
ASA 3 22 (61%)
ASA 4 3 (8.3%)
Body mass index (mean) 24.63
Smoking at baseline e no. (%) 15 (41.6%)
Hypertension e no. (%) 28 (77.7%)
Diabetes mellitus e no. (%) 9 (25%)
Hyperlipidaemia e no. (%) 30 (83.3%)
Coronary artery disease e no. (%) 18 (50%)
History of myocardial infarction e no. (%) 11 (30.5%)
History of stroke 4 (11.1%)
Cancer 4 (11.1%)
Renal failure
60 > creatinin clearance > 30 ml mn1 6 (16.6%)
Creatinin clearance < 30 ml mn1 0
Rutherford category of peripheral
artery disease, n(%)
2: moderate claudication 5 (12.5%)
3: severe claudication 23 (57.5%)
4: ischaemic pain at rest 5 (12.5%)
5: minor tissue damage 7 (17.5%)
Postoperative treatment
Antiplatelet treatment 31 (86.2%)
Oral anticoagulant treatment 1 (2.7%)
Antiplatelet and oral anticoagulant
treatments
4 (11.1%)
Statins 29 (80.5%)
Smoking was defined as active smoking.
Table 2 Baseline angiographic and interventional data.
Variables
Type of lesion e no. of treated limbs (%)
Type I 8 (20%)
Type II 17 (42.5%)
Type III 10 (25%)
Type IV 5 (12.5%)
Degree of stenosis e no. of treated limbs (%)
70e90% 21 (52.5%)
>90% 19 (47.5%)
Runoff score 1.53
TASC classification for femoro-popliteal disease
A 3 (7.5%)
B 8 (20%)
C 4 (10%)
D 13 (32.5%)
Type of anaesthesiology
Local 33 (91.6%)
General 3 (8.4%)
Procedure approach e no. of treated limbs (%)
Over-the-bifurcation approach 27 (67.5%)
Ipisilateral femoral approach 4 (10%)
Humeral approach 9 (22.5%)
Type of lesion e type of stent (balloon-expendable/
self expendable)
Type I 0/8
Type II 0/17
Type III 5/8
Type IV 0/5
TASC: TransAtlantic Inter-Society Consensus. 12 patients were
not classified for TASC classification because of the absence of
femoro-popliteal lesions.
Table 3 Concomitant endovascular procedures.
Endovascular repair e no. (%)
CFA alone 16 (40%)
CFA þ iliac artery 15 (37.5%)
CFA þ SFA 9 (22.5%)
CFA þ iliac artery þ SFA 0
CFA: common femoral artery; SFA: superficial femoral artery.
790 L. Aze´ma et al.was used to treat 27 CFA (67.5%). Nine CFA were treated by
a brachial approach. The brachial approach was performed
because of obesity, previous aortobifemoral bypass and aortic
endograft. In four cases, an ipsilateral approach was chosen
via the CFA for type 1 lesions or via the SFA for type 2 lesions.
When the SFA was the vessel accessed, the puncture was
performed at the first centimetres of the SFA and a femoral
closure device was used to prevent bleeding or pseudo-
aneurysm. Predilatationwas performed for five limbs (12.5%).
Forty-three stents were implanted and four types of
commercially available stents were used: Amiia (Cordis),
Everflex (EV3), E-Luminexx (Bard) and Flexstar (Bard).
Mainly self-expandable stents were used (88.3%). Balloon-
expandable stents were chosen to treat five lesions of type III.
In one patient, a femoro-poplitaeal bypass was associated
with a type I lesion. Concomitant endovascular treatmentwas
performed in 24 cases (60%): in 15 cases to improve inflow and
in nine cases to improve outflow (Table 3).
Perioperative data
No patient was lost to follow-up. No patient required
intensive unit care. The perioperative morbid-mortalityrate was 5% (n Z 2). One patient required re-intervention
for a haematoma at the femoral puncture site after an
over-the-bifurcation approach. One patient required
a major amputation. This patient presented a critical limb
ischaemia with extensive lesion to the foot. No distal
revascularisation was possible. CFA stenting was done prior
to a transtibial amputation. The patient went on to recover
from the transtibial amputation. The mean length of
hospital stay was 2.9 days (range 1e15 days). The median
length of hospital stay was 2 days. Three patients were
hospitalised in the context of day-case vascular procedure.
In these cases, an arterial femoral closure device
(Angioseal 6F, St Jude Medical) was used to allow early
discharge. Other patients were hospitalised for 2 days
Common Femoral Artery Stenting 791according to routine hospitalisation. Length of hospital stay
was extended in patients, who required wound care or re-
intervention. One patient was discharged at 15 days
following a femoro-poplitaeal bypass associated with CFA
stenting (type I lesion). During the 1-month period, survival
rate was 100%. The primary sustained clinical improvement
was 82.5%. According to the Rutherford scale for gauging
changes in clinical status, clinical status was improved in 33
limbs. Seven limbs were considered not improved. One
patient with critical limb ischaemia underwent a transtibial
amputation. The clinical status of two patients, who pre-
sented claudication and critical limb ischaemia, remained
unchanged. Finally, four patients with critical ischaemia
and tissue loss were improved but not completely healed
and, therefore, were considered not improved. Other
patients with critical ischaemia healed. The 1-month
primary patency rate was 100% and no in-stent restenosis
was observed. Moreover, no stent fracture was noted. No
patient required surgical conversion or secondary endo-
vascular treatment within the first month.Figure 2 Stent fracture. Stent fracture (arrow) observed at 6
months based on x-ray interpretation. This fracture was clas-
sified as a type III and occurred in the first centimetres of the
external iliac artery.
Figure 3 Target lesion revascularisation-free cumulative
survival.Follow-up
Complete follow-up data were obtained for all limbs at 12
months. Mean follow-up was 22 months. At 6 months of
follow-up, both primary and secondary sustained clinical
improvements were 90%. At 12 months of follow-up,
primary and secondary sustained clinical improvement
were 80% and 90%, respectively.
During this study, one stent fracture was noted at 6
months basedonX-ray interpretation. The stent fracturewas
classified as a type 3 and occurred in a patient treated by
anitinol stent for a type I CFA lesion (Fig. 2). This fracturewas
associated with in-stent restenosis within 12 months.
At 12 months, we observed eight cases of in-stent
restenosis (20%). In four cases, restenosis was not critical
and the patients were still asymptomatic. Therefore, no re-
intervention was performed. In two cases, endovascular
procedures were required to treat in-stent restenosis by
balloon angioplasty. In two other cases, open procedures
were preferred to treat in-stent restenosis because of
severe aorto-iliac atherosclerotic lesions, which had prob-
ably been underestimated. With a univariate logistic
model, any risk factors (age, sex, diabetes, stage of
peripheral artery disease, types of CFA lesions, types of
stents, TASC status and runoff) were not significantly
associated with in-stent restenosis at 12 months.
TLR- and TER-free cumulative survival are represented
in Figs. 3 and 4. At 1 year, TLR- and TER-free cumulative
survival were 85% and 80%, respectively. At 6 months, one
patient underwent open redo procedure (aortobifemoral
and femoro-tibial bypasses) and two patients underwent
a venous femoro-poplitaeal bypass between the profunda
femoris artery and the below-knee poplitaeal artery.
Between 6 and 12 months, three other patients underwent
redo procedures. CFA angioplasty was performed for in-
stent restenosis in two patients and aortofemoral bypass
was performed in the other case. With univariate Cox
analysis, only age was a significant predictor (p Z 0.05) of
a TLR event. There were no significant predictors of a TER
event.Discussion
Over the perioperative period, this study has shown that
endovascular repair of the CFA and concomitant arterial
lesions are feasible and safe procedures. At 12 months, the
sustained clinical improvements were acceptable even if
the occurrence of in-stent restenosis should be taken into
account.
Figure 4 Target extremity revascularisation-free cumulative
survival.
792 L. Aze´ma et al.This study has some limitations. Even though this study is
prospective, there is no control group and no randomisation.
Patients were included at the discretion of the surgeon, the
number of interventions is relatively small and the patient
group is heterogeneous. Indeed, we havemixed intermittent
claudication and critical ischaemia. The follow-up is short.
Finally, a subjective clinical scale was used for the primary
end point evaluation and the ankleebrachial index or
treadmill exercise testing was not systematically performed
to objectively evaluate patients’ outcomes. Regarding
statistical analysis, multivariable assessment in Cox models
was not powered to individuate independent predictors.
To our knowledge, we propose here the first classifica-
tion of CFA atherosclerotic disease. This classification in
four types is based on the findings of Lopez.7 In 1989, Lopez
et al. studied the anatomical behaviour of the CFA when
the hip joint passes from the position of extension to the
position of flexion at 90, using several methods such as
anatomic sections, arteriography or vascular casts. During
flexion of the hip joint, the CFA undergoes a movement of
combined torsion on its axis and flexion at two different
points on its course: the inguinal ligament above, repre-
senting the lower limit of the external oblique muscle, and
the Sartorius muscle below. These two points divide the
CFA into three parts that represent the first types. Type 4
represents stenotic bypass anastomoses. This type of lesion
is particular as the stenosis is due to intimal hyperplasia.
In 2004, Stricker reported the results of a retrospective
study regarding the stent-assisted angioplasty at the level
of the CFA.10 In this study 33 limbs were treated. At 3 years,
83% of the arteries were patent and five restenosis were
observed. According to Stricker, the risk of in-stent reste-
nosis could be higher for bypass anastomoses (type IV
lesions).
The main reasons to choose endovascular repair rather
than open repair for treating CFA is related to the advan-
tages of mini-invasive procedures and the possibility to
treat all the lesions by an endovascular technique. In one
case, endovascular repair was performed in a patient
undergoing concomitant distal bypass with the groin
already exposed. In this case, CFA lesions werepreoperatively underestimated and its repair was not
scheduled. Hospital length of stay and perioperative
morbidity are both reflective of the less invasive procedure.
In our series, average hospital stay was 2.9 days. In
comparison, Kang reported an average hospital stay of 3.2
days for open CFA procedures.3 Factors such as local
anaesthesia, percutaneous approach and use of arterial
closure device could allow a shorter hospital length of stay
in favour of the endovascular procedure. Similarly, endo-
vascular treatment is considered to decrease the rate of
perioperative morbidity. Our study reports a perioperative
morbid-mortality rate of 5%. In Cardon’s study,2 the local
morbidity rate was 21.6% with 18% of minor complications
(haematoma and lymph link) and 3.6% of complications
requiring a re-intervention. More recently, Kang reported
13.8% of complications after CFA endarterectomy and Bal-
lotta noted 0% of major complications and 6.6% of local
complications.3,18 These studies were retrospective and
complications, such as postoperative dysaesthesia, were
probably underestimated. With respect to the second issue,
CFA endovascular repair could be performed to obtain
a “total endovascular look.” We showed that, in over half of
the cases, CFA stenting was combined with an inflow or
outflow ipsilateral endovascular procedure. Kang et al.
have reported a similar rate by performing 57% of hybrid
procedures during CFA endarterectomy.3 On the other
hand, isolated lesions of CFA (type II lesions) e though
uncommon e are frequently associated with disabling
peripheral ischaemic symptoms. In our study, 42.5% of the
lesions were type 2 lesions, and indications for repair were
claudication in 76% and critical limb ischaemia in 24%. In
comparison, Mukherjee and Springhorn et al. reported open
repair for isolated atherosclerotic lesions of the CFA for
symptoms of critical limb ischaemia in 41% and 69%,
respectively.19,20 More recently, Ballota reported that
claudication was the indication for surgery in 60% and
critical limb ischaemia in 40% of the patients undergoing
CFA endarterectomy.18
One serious consideration is that stenting of the CFA may
complicate further open surgical procedures. In this study,
two patients underwent extremity revascularisation
procedures by venous femoro-poplitaeal bypass at 6
months. Because of the absence of in-stent restenosis at
the CFA level, venous bypasses were performed between
the profunda femoris artery and the below-knee popliteal
artery. In case of in-stent restenosis, the CFA stent should
be removed by performing a CFA endarterectomy. Endo-
vascular repair of CFA may result in compromising the flow
to the profunda femoris artery. For this reason, in type II
and III lesions, we recommend to first catheterise the pro-
funda femoris artery and to keep a guide into this artery
during the entire procedure. Concerns of this technique are
also related to the risk of stent fracture and the loss of the
femoral approach for further percutaneous procedures. For
certain clinicians, CFA stenting precludes further endovas-
cular interventions at the puncture site. However, the CFA
could be punctured under either fluoroscopic guidance or
duplex scan just above or below the stent to prevent strut
damage but increasing the risk of bleeding or pseudo-
aneurysms. Second, different approaches using radial,
brachial or ipsilateral SFAs could be used. Regarding the risk
of stent fracture, effects of joint motion on the structural
Common Femoral Artery Stenting 793integrity of periarticular stents are a concern to perform
endovascular therapy. Indeed, stent fractures occur mostly
in the bending vascular segments close to joints, such as
femoro-popliteal and femoral segments.21 In this study, we
have reported one case of stent fracture. The fracture
occurred above the inguinal ligament. Interestingly, this
location was defined by Lopez as a point of flexibility where
the artery undergoes a movement of combined torsion on
its axis and flexion.7
At 12 months, the CFA in-stent restenosis rate was 20%.
Even though there was no significant correlation between
the occurrence of in-stent restenosis and any adjusted
factors, in-stent restenosis seemed particularly frequent
with type III lesions. In this case, stents are implanted just
in front of the Sartorius muscle. Consequently, the Sartorius
muscle could alter the structural integrity of the stent and
the arterial wall.
In conclusion, endovascular repair of the CFA seems to
be a safe technique of revascularisation, with acceptable
initial results at 12 months. However, endovascular repair
of the CFA mandates ongoing surveillance and longer
follow-up, given the great mobility of the hip joint and the
dynamic modification of the femoral artery. Thanks to this
pilot study, a French randomised and controlled trial has
been set up to compare open and endovascular procedures
for the treatment of CFA atherosclerotic lesions. This trial
has obtained a secured financial support from the National
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